NCT06214650

Brief Summary

Diastasis recti abdominis is a pathology that appears in a high percentage of women during the postpartum period. However, there is little evidence about its treatment. The present protocol aims to evaluate the efficacy of radiofrequency as an alternative for the treatment of abdominal diastasis along with abdominal exercises compared to the only intervention through abdominal exercise. An aleatory clinical testing will be conducted where 44 women diagnosed with diastasis recti abdominis in the postpartum period will be recruited. A common exercise protocol will be applied for two groups of participants, and both of them will have to be able to carry out the activities autonomously at home. In addition, control sessions will be held weekly for both groups where one of the groups, the control group (n=22), will receive radiofrequency therapy with the machine in athermic mode, while the other group, the experimental group (n=22), will receive a weekly session under the established diathermy protocol. The sessions will last 30 minutes and will take place for 10 consecutive weeks. Three variables will be evaluated: the width of the diastasis measured in centimeters, life quality measured using the Short form (36) questionnaire, and the perception of the pain measured with the visual analogue scale. Three evaluations will be done: at the beginning of the study, after ten weeks and three months later.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
44mo left

Started Sep 2024

Longer than P75 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress32%
Sep 2024Dec 2029

First Submitted

Initial submission to the registry

December 27, 2023

Completed
23 days until next milestone

First Posted

Study publicly available on registry

January 19, 2024

Completed
8 months until next milestone

Study Start

First participant enrolled

September 1, 2024

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2029

Last Updated

May 8, 2024

Status Verified

May 1, 2024

Enrollment Period

2.2 years

First QC Date

December 27, 2023

Last Update Submit

May 7, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Width of the diastasis recti abdominis

    The inter-recti diastasis will be measured with a transabdominal ultrasound using a lineal transductor. It will be assessed three measures: 2cm and 5cm above the umbilicus and 2cm below the umbilicus.

    It will be collected two measures to compare the changes: at baseline to the study and ten weeks later.

Secondary Outcomes (2)

  • Participant's quality of life

    At baseline pre intervention and inmediately after the intervention (10 weeks later)

  • Low back pain

    At baseline pre intervention and inmediately after the intervention (10 weeks later)

Study Arms (2)

Radiofrequency group

EXPERIMENTAL

All participants will be receive two interventions: 1. A weekly session for 10 weeks with radiofrequency. It will be use the protocol of INDIBA. Each session will last 30 minutes. 2. Participants will do an homely exercise protocol. This protocol will practise for 3 days at week.

Other: Radiofrequency

Control group

ACTIVE COMPARATOR

All participants will be receive two interventions: 1. A weekly session for 10 weeks with radiofrequency. It will be use INDIBA without intensity such as a placebo. Each session will last 30 minutes. 2. Participants will do an homely exercise protocol. This protocol will practise for 3 days at week.

Other: Control

Interventions

Experimental group will receive the common exercise program associated with a radiofrequency treatment using INDIBA® (INDIBA Activ 7, Barcelona, INDIBA S.A.) at a frequency of 448 hertz. It will use the capacitive electrode as a method of preparation and vascularization of the superficial tissues and immediately, within the same session, the resistive electrode to stimulate deep tissues. This treatment is based on the protocols established by INDIBA® S.A. It will consist of one weekly diathermy session of thirty minutes during ten weeks. The use of diathermy will not be interrupted throughout the session. The common exercise program consist in a ten abdominal exercises (including recti abdominis, transversus and obliques). It will practised at home only just three days at week.

Radiofrequency group
ControlOTHER

Control group will receive a weekly INDIBA® session in the abdominal area with the same protocol as the experimental group in athermic mode (placebo treatment) and the common exercise program. The session will last thirty minutes and will be carried out by the research physiotherapist during ten weeks.

Control group

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Women diagnosed with diastasis recti abdominis (DRA)
  • Age range18-45 years old
  • Women not DRA treated previously
  • Women not diagnosed with umbilical hernia

You may not qualify if:

  • DRA width less than 2.5cm
  • Women diagnosed with intestinal disease such as irritable bowel syndrome (IBS) or Chron disease.
  • Women looking for a new pregnancy or pregnant women.
  • Women who can not receive diathermy treatment (e.g tumoral process, open wound in the abdominal area or any diathermy contraindication).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Diastasis Recti And Weakness Of The Linea Alba

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 27, 2023

First Posted

January 19, 2024

Study Start

September 1, 2024

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2029

Last Updated

May 8, 2024

Record last verified: 2024-05